Although Sphk1 is a potential candidate in AD pathology, it is an indirect regulator of microglial phagocytic activity that involves neuronal actions, whereas N-AS, a sphingosine metabolic intermediate, is a newly reported direct regulator of COX2 acetylation and microglial phagocytic activity. The gene discussed is SPHK1; the disease is Alzheimer disease.